Cooperativity is a phenomenon where individual components of a system influence each other so that they act collectively rather than independently. In biochemistry, it most often describes how a protein with multiple binding sites changes its behavior as each site gets occupied: the first molecule that binds makes it easier (or harder) for the next one to bind. This creates an all-or-nothing response that lets your body react sharply to small changes in its environment.
How Cooperativity Works
Imagine a protein with four binding sites. Without cooperativity, each site would fill up independently, and the protein would gradually become saturated as the concentration of its binding partner increases. With cooperativity, the story changes. When the first molecule binds, it triggers a shape change in the protein that ripples through to the other sites, altering their binding strength. The second molecule binds more readily than the first, the third more readily than the second, and so on.
This chain reaction happens because proteins can exist in two structural states. One is called the “tense” state, which has low binding affinity. The other is the “relaxed” state, which binds its target much more easily. Each binding event tips the balance, making the protein more likely to flip from tense to relaxed. Once it flips, every remaining empty site suddenly becomes far more welcoming. The result is a rapid, switch-like transition from mostly empty to mostly full over a narrow range of concentration.
Hemoglobin: The Classic Example
Hemoglobin is the textbook case of cooperativity, and for good reason. It’s a protein made of four subunits, each carrying a binding site for oxygen. In its deoxygenated form, hemoglobin sits in the tense state. Constraints between subunits resist the structural changes that oxygen binding tries to produce, keeping overall affinity low. But when the first oxygen molecule binds to one of the four sites, it destabilizes the tense state and nudges the entire protein toward the relaxed state. In the relaxed state, those intersubunit constraints release, and the remaining sites bind oxygen with much higher affinity.
At the molecular level, a network of linkages between amino acid chains holds the tense structure together. Oxygen binding at one site breaks some of these linkages and triggers a rotation between the two halves of the hemoglobin molecule. Research using hydrogen exchange techniques has shown that specific sites at the interfaces between subunits are stabilized by about 1.5 kilocalories per mole more in the relaxed state than in the tense state, confirming that the relaxed form is genuinely a more stable structure once oxygen is present.
This cooperativity is what produces hemoglobin’s famous S-shaped (sigmoidal) oxygen binding curve, first described by Bohr, Hasselbalch, and Krogh in 1904. The curve means hemoglobin picks up oxygen efficiently in the lungs, where oxygen levels are high, and releases it efficiently in tissues, where oxygen levels are low. In humans, hemoglobin reaches 50% oxygen saturation at a pressure of about 26.9 mmHg (at normal body temperature and pH). Compare this to myoglobin, a single-subunit protein in muscle that lacks cooperativity entirely: myoglobin produces a simple hyperbolic curve and holds onto its oxygen much more tightly. Without hemoglobin’s cooperative behavior, oxygen delivery to your tissues would be far less responsive to changing demands.
Positive vs. Negative Cooperativity
What hemoglobin demonstrates is positive cooperativity: each binding event makes the next one easier. This creates the sharp, sigmoidal response curve that acts like a biological switch, flipping from “off” to “on” over a narrow range.
Negative cooperativity works in the opposite direction. When the first molecule binds, it makes subsequent binding harder. This produces a response curve that is shallower than what you’d see with independent binding, spreading the protein’s response over a wider range of concentrations. Negative cooperativity is useful when a system needs to be sensitive across a broad range rather than switching sharply at one threshold. Some enzymes and receptors use negative cooperativity to maintain a graded, proportional response to their signals.
Measuring Cooperativity With the Hill Coefficient
Scientists quantify cooperativity using a value called the Hill coefficient, derived from fitting binding data to the Hill equation. A Hill coefficient of 1 means no cooperativity at all: each site binds independently. Values greater than 1 indicate positive cooperativity, and values less than 1 suggest negative cooperativity. Hemoglobin, with four binding sites, has a Hill coefficient of about 2.8, not quite 4 because the cooperativity isn’t perfectly all-or-nothing, but high enough to produce a strongly sigmoidal curve.
In practice, the Hill coefficient is rarely as high as the total number of binding sites. It’s best understood as an index of how collective the binding behavior is, not a literal count of how many sites participate simultaneously. One common misconception is that any Hill coefficient above 1 automatically proves positive cooperativity along the reaction pathway. In certain gating models, a value of 1.17 can arise even when subunits have identical binding strengths, so context matters when interpreting these numbers.
Two Competing Models
Two foundational models explain how cooperativity arises, and they differ in one key assumption. The concerted model, proposed by Monod, Wyman, and Changeux, says that all subunits of a protein switch shape together. The entire molecule flips from tense to relaxed as a unit. No subunit can be relaxed while its neighbors remain tense. Binding oxygen simply shifts the equilibrium between these two pre-existing states.
The sequential model, proposed by Koshland, Némethy, and Filmer, allows each subunit to change shape independently when it binds a ligand. In this view, binding at one site induces a local shape change that then influences neighboring subunits through direct contact, gradually increasing their affinity. The protein doesn’t have to flip all at once.
Real proteins often behave in ways that borrow from both models. Hemoglobin, for instance, shows strong evidence of concerted switching at the level of its overall structure, but some of its intermediate states hint at sequential changes within individual subunits. Modern structural techniques, including mass spectrometry methods that can capture proteins in the act of changing shape, continue to reveal how these mechanisms blend in practice.
Cooperativity Beyond Oxygen Transport
Cooperativity is not limited to hemoglobin or even to proteins binding small molecules. It plays a central role in gene regulation. Transcription factors, the proteins that turn genes on and off, often bind cooperatively to DNA. When one transcription factor attaches to its target sequence, it can enhance the binding affinity of a second transcription factor at a nearby site. This cooperative binding at gene promoters and enhancers strongly increases gene expression, creating the sharp on/off control cells need to respond to developmental signals or environmental changes.
The mechanisms behind cooperative DNA binding vary. In some cases, two transcription factors physically touch each other after binding, stabilizing both on the DNA. This type of cooperativity typically requires the binding sites to be a specific distance apart. In other cases, the first protein alters the local DNA structure or accessibility in a way that helps the second protein bind, without the two ever making direct contact. This distance-independent form of cooperativity can even be asymmetric: protein A helps protein B bind, but protein B doesn’t necessarily return the favor. The DNA sequence linking the two binding sites can also modulate how strong the cooperative effect is.
Why Cooperativity Matters for Drug Design
Cooperativity has become increasingly important in drug development, particularly in the design of allosteric modulators. These are drugs that bind to a protein at a site separate from the main active site. Because allosteric sites are less similar across related proteins than active sites are, drugs targeting them can be more selective, reducing side effects. They also avoid having to compete with the body’s own molecules for the active site, which can improve potency.
Understanding the cooperative communication between the main binding site and allosteric pockets helps researchers predict how a drug will alter protein function. If a drug stabilizes the relaxed state of a protein, it can amplify the protein’s natural response. If it stabilizes the tense state, it can dampen it. This fine-tuned control is a major advantage over drugs that simply block the active site entirely, and it’s driving significant interest in mapping the structural details of cooperativity across drug targets.